Platelet CD154 potentiates interferon-α secretion by plasmacytoid dendritic cells in systemic lupus erythematosus

Science Translational Medicine

Volumn 2, Issue 47, 2010, Pages

  Duffau, Pierre ^a,b,c,d   Seneschal, Julien ^a,b,c,d   Nicco, Carole ^e   Richez, Christophe ^a,b,c,d   Lazaro, Estibaliz ^d   Douchet, Isabelle ^a,b,c   Bordes, Cécile ^a,b,c,d   Viallard, Jean François ^d   Goulvestre, Claire ^e   Pellegrin, Jean Luc ^d   Weil, Bernard ^e   Moreau, Jean François ^a,b,c,d   Batteux, Frédéric ^e   Blanco, Patrick ^a,b,c,d  

^a CNRS Bordeaux Segalen University   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c IFR 66   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CD40 ANTIGEN; CD40 LIGAND; CLOPIDOGREL; DEOXYRIBONUCLEASE; DOUBLE STRANDED DNA; FC RECEPTOR IIA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 6; PADGEM PROTEIN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FC RECEPTOR; TICLOPIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; NONHUMAN; OVERALL SURVIVAL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION; ANIMAL; BLOOD; DENDRITIC CELL; DISEASE MODEL; DRUG EFFECT; IMMUNOLOGY; MOUSE; SECRETION; THROMBOCYTE;

ANIMALS; AUTOANTIBODIES; BLOOD PLATELETS; CD40 LIGAND; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, IGG; TICLOPIDINE;

EID: 77956454663     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001001     Document Type: Article

References (49)

1. G. Ruiz-Irastorza, M. A. Khamashta, G. Castellino, G. R. Hughes, Systemic lupus erythematosus. Lancet 357, 1027-1032 (2001).
2. M. Nikpour, M. B. Urowitz, D. D. Gladman, Epidemiology of atherosclerosis in systemic lupus erythematosus. Curr. Rheumatol. Rep. 11, 248-254 (2009).
3. J. Banchereau, V. Pascual, Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25, 383-392 (2006).
4. A. A. Bengtsson, G. Sturfelt, L. Truedsson, J. Blomberg, G. Alm, H. Vallin, L. Rönnblom, Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9, 664-671 (2000).
5. L. Bennett, A. K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, V. Pascual, Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003).
6. E. C. Baechler, F. M. Batliwalla, G. Karypis, P. M. Gaffney,W. A. Ortmann, K. J. Espe, K. B. Shark, W. J. Grande, K. M. Hughes, V. Kapur, P. K. Gregersen, T. W. Behrens, Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U.S.A. 100, 2610-2615 (2003).
7. F. J. Barrat, T. Meeker, J. Gregorio, J. H. Chan, S. Uematsu, S. Akira, B. Chang, O. Duramad, R. L. Coffman, Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131-1139 (2005).
8. S. R. Christensen, J. Shupe, K. Nickerson, M. Kashgarian, R. A. Flavell, M. J. Shlomchik, Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-428 (2006).
9. P. Pisitkun, J. A. Deane, M. J. Difilippantonio, T. Tarasenko, A. B. Satterthwaite, S. Bolland, Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312, 1669-1672 (2006).
10. K. Jurk, B. E. Kehrel, Platelets: Physiology and biochemistry. Semin. Thromb. Hemost. 31, 381-392 (2005).
11. D. A. Dixon, N. D. Tolley, K. Bemis-Standoli, M. L. Martinez, A. S. Weyrich, J. D. Morrow, S. M. Prescott, G. A. Zimmerman, Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J. Clin. Invest. 116, 2727-2738 (2006).
12. J. E. Freedman, J. Loscalzo, Platelet-monocyte aggregates: Bridging thrombosis and inflammation. Circulation 105, 2130-2132 (2002).
13. B. D. Elzey, J. Tian, R. J. Jensen, A. K. Swanson, J. R. Lees, S. R. Lentz, C. S. Stein, B. Nieswandt, Y. Wang, B. L. Davidson, T. L. Ratliff, Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 19, 9-19 (2003).
14. V. Henn, J. R. Slupsky, M. Gräfe, I. Anagnostopoulos, R. Förster, G. Müller-Berghaus, R. A. Kroczek, CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591-594 (1998).
15. N. Li, Platelet-lymphocyte cross-talk. J. Leukoc. Biol. 83, 1069-1078 (2008).
16. A. C. Grammer, P. E. Lipsky, CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum. 46, 1417-1429 (2002).
17. S. Danese, C. Fiocchi, Platelet activation and the CD40/CD40 ligand pathway: Mechanisms and implications for human disease. Crit. Rev. Immunol. 25, 103-121 (2005).
18. K. Kato, E. Santana-Sahagún, L. Z. Rassenti, M. H. Weisman, N. Tamura, S. Kobayashi, H. Hashimoto, T. J. Kipps, The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J. Clin. Invest. 104, 947-955 (1999).
19. L. Rönnblom, G. V. Alm, Systemic lupus erythematosus and the type I interferon system. Arthritis Res. Ther. 5, 68-75 (2003).
20. L. McGregor, J. Martin, J. L. McGregor, Platelet-leukocyte aggregates and derived microparticles in inflammation, vascular remodelling and thrombosis. Front. Biosci. 11, 830-837 (2006).
21. P. Blanco, A. K. Palucka, M. Gill, V. Pascual, J. Banchereau, Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294, 1540-1543 (2001).
22. M. W. Boulé, C. Broughton, F. Mackay, S. Akira, A. Marshak-Rothstein, I. R. Rifkin, Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J. Exp. Med. 199, 1631-1640 (2004).
23. J. Graff, S. Harder, O. Wahl, E. H. Scheuermann, J. Gossmann, Anti-inflammatory effects of clopidogrel intake in renal transplant patients: Effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin. Pharmacol. Ther. 78, 468-476 (2005).
24. J. N. George, Platelets. Lancet 355, 1531-1539 (2000).
25. M. Gawaz, H. Langer, A. E. May, Platelets in inflammation and atherogenesis. J. Clin. Invest. 115, 3378-3384 (2005).
26. G. S. Early, W. Zhao, C. M. Burns, Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J. Immunol. 157, 3159-3164 (1996).
27. T. Higuchi, Y. Aiba, T. Nomura, J. Matsuda, K. Mochida, M. Suzuki, H. Kikutani, T. Honjo, K. Nishioka, T. Tsubata, Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J. Immunol. 168, 9-12 (2002).
28. A. C. Grammer, R. Slota, R. Fischer, H. Gur, H. Girschick, C. Yarboro, G. G. Illei, P. E. Lipsky, Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. 112, 1506-1520 (2003).
29. M. Koshy, D. Berger, M. K. Crow, Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest. 98, 826-837 (1996).
30. A. Desai-Mehta, L. Lu, R. Ramsey-Goldman, S. K. Datta, Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J. Clin. Invest. 97, 2063-2073 (1996).
31. A. L. Peters, L. L. Stunz, G. A. Bishop, CD40 and autoimmunity: The dark side of a great activator. Semin. Immunol. 21, 293-300 (2009).
32. U. Båve, M. Magnusson, M. L. Eloranta, A. Perers, G. V. Alm, L. Rönnblom, FcgRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J. Immunol. 171, 3296-3302 (2003).
33. M. Fernández, G. S. Alarcón, M. Apte, R. M. Andrade, L. M. Vilá, J. D. Reveille; LUMINA Study Group, Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum. 56, 614-621 (2007).
34. M. J. Roman, B. A. Shanker, A. Davis, M. D. Lockshin, L. Sammaritano, R. Simantov, M. K. Crow, J. E. Schwartz, S. A. Paget, R. B. Devereux, J. E. Salmon, Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2399-2406 (2003).
35. Y. Asanuma, A. Oeser, A. K. Shintani, E. Turner, N. Olsen, S. Fazio, M. F. Linton, P. Raggi, C. M. Stein, Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2407-2415 (2003).
36. S. Kinlay, G. G Schwartz, A. G. Olsson, N. Rifai, W. J. Sasiela, M. Szarek, P. Ganz, P. Libby; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators, Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110, 386-391 (2004).
37. T. Aprahamian, R. Bonegio, J. Rizzo, H. Perlman, D. J. Lefer, I. R. Rifkin, K. Walsh, Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J. Immunol. 177, 3028-3034 (2006).
38. E. Boilard, P. A. Nigrovic, K. Larabee, G. F. Watts, J. S. Coblyn, M. E. Weinblatt, E. M. Massarotti, E. Remold-O'Donnell, R. W. Farndale, J. Ware, D. M. Lee, Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327, 580-583 (2010).
39. M. C. Hochberg, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 40, 1725 (1997).
40. C. Natal, P. Restituto, C. Iñigo, I. Colina, J. Díez, N. Varo, The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. J. Clin. Endocrinol. Metab. 93, 2319-2327 (2008).
41. Q. Tian, J. Taupin, S. Elledge, M. Robertson, P. Anderson, Fas-activated serine/threonine kinase (FAST) phosphorylates TIA-1 during Fas-mediated apoptosis. J. Exp. Med. 182, 865-874 (1995).
42. P. Legembre, P. Moreau, S. Daburon, J. F. Moreau, J. L. Taupin, Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas. Cell Death Differ. 9, 329-339 (2002).
43. U. Båve, G. V. Alm, L. Rönnblom, The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer. J. Immunol. 165, 3519-3526 (2000).
44. K. Yasuda, C. Richez, M. B. Uccellini, R. J. Richards, R. G. Bonegio, S. Akira, M. Monestier, R. B. Corley, G. A. Viglianti, A. Marshak-Rothstein, I. R. Rifkin, Requirement for DNA CpG content in TLR9-dependent dendritic cell activation induced by DNA-containing immune complexes. J. Immunol. 183, 3109-3117 (2009).
45. W. Bergmeier, K. Rackebrandt, W. Schröder, H. Zirngibl, B. Nieswandt, Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood 95, 886-893 (2000).
46. WAF1/CIP1 ameliorates murine lupus. J. Immunol. 175, 6959-6967 (2005).
47. R. M. Wernick, D. L. Smith, D. C. Houghton, D. S. Phillips, J. L. Booth, D. N. Runckel, D. S. Johnson, K. K. Brown, C. L. Gaboury, Reliability of histologic scoring for lupus nephritis: A community-based evaluation. Ann. Intern. Med. 119, 805-811 (1993).
48. L. Dong, S. Ito, K. J. Ishii, D. M. Klinman, Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum. 52, 651-658 (2005).
49. Acknowledgments: We thank J. C. Carron, M. Garcie, D. Aufrere, V. Pitard, F. Mouginot, and all members of the Laboratory of Clinical Immunology at the Centre Hospitalier Régional de Bordeaux who contributed to this study. We thank A. Taïeb and T. Aprahamian for critically reading the manuscript and for their helpful comments. Funding: This work was supported by CNRS. Author contributions: P.D., J.S., and I.D. did the experiments on human SLE. P.B., J.-F.M., and C.B. wrote the paper. C.N., F.B., C.R., and B.W. did the experiment on mice. E.L., J.-F.V., and J.-L.P. conducted the sampling and clinical study of SLE patients. P.D., J.S., and F.B. participated in the interpretation of the results and the editing of the manuscript. Competing interests: The authors declare that they have no competing interests.